Cell Therapy Deals Are Up 800% in 2026 — Here's the Data

Cell therapy deal activity surged 800% between March and September 2026, jumping from zero completed transactions in the prior six-month window to eight deals — several of them blockbuster-scale. This isn't a gentle uptick; it's a category-wide land grab driven by Big Pharma's urgent need to own next-generation cell therapy platforms before the autologous-to-allogeneic transition locks in competitive moats for the next decade.

The Data — Cell Therapy Deal Activity, Period over Period

The baseline here matters. Zero deals in the September 2025–March 2026 window isn't a data artifact — it reflects a genuine pause. Cell therapy licensing stalled through late 2025 as pharma BD teams digested the implications of CAR-T manufacturing bottlenecks, CMS reimbursement uncertainty, and a string of clinical holds. The dam broke in Q2 2026. When it did, the capital deployed was extraordinary.

What's Driving the Trend

Three forces converged to produce this cell therapy deal trends 2026 pattern. First, manufacturing readiness crossed a threshold. Companies like MaxCyte and Bio-Techne have spent years building scalable, non-viral gene delivery and cell engineering platforms. By mid-2026, these platforms demonstrated consistent GMP-grade output at scales that finally made allogeneic and iPSC-derived programs commercially viable — not just clinically interesting. Pharma R&D leadership noticed.

Second, pipeline gaps became existential. Novartis's Kymriah franchise is aging. Bristol Myers Squibb's Abecma and Breyanzi face biosimilar-like competitive pressure from next-gen constructs. Lilly, Roche, and Merck KGaA — none of whom had credible cell therapy franchises 18 months ago — moved aggressively because the window to acquire differentiated platforms is closing. The Kelonia–Lilly deal at $7B TDV and the Poseida–Roche deal at $1.5B TDV are defensive moves dressed up as offensive strategy. These companies cannot afford to build internally on a 7-year timeline when competitors are buying 3-year shortcuts.

Third, the FDA's evolving regulatory posture on allogeneic cell therapies created a green light. Updated guidance on potency assays and comparability protocols for off-the-shelf cell products, issued in Q1 2026, reduced a major source of regulatory risk that had been suppressing deal appetite. BD teams that had been circling targets for 12+ months suddenly had the regulatory clarity to close. When you see cell therapy licensing 2026 activity spike this fast after a dead period, it's almost always a regulatory unlock combined with pent-up strategic demand.

Notable Deals

The Merck KGaA–Bio-Techne transactions dominate this dataset. Two deals within two weeks totaling over $22B in combined deal value represent the single largest cell therapy licensing commitment by any European pharma in history. The structure — an initial platform licensing deal followed by what appears to be an expanded or full acquisition — signals Merck KGaA's intent to own, not rent, its cell engineering infrastructure. This is a bet on becoming the supplier to the ecosystem, not just a therapeutic developer. Compare this to historical Deal Benchmarks for platform deals and the premium is stark: median TDV for enabling technology licenses in cell therapy sat at roughly $800M through 2024–2025.

Kelonia's $7B TDV deal with Lilly is the standout for early-stage cell therapy licensing 2026 valuations. Kelonia's lentiviral vector platform is preclinical-heavy, which makes a $7B headline number aggressive by any measure. Lilly is paying for optionality across multiple future programs — a structure that reflects the current seller's market for differentiated delivery platforms. Poseida's $1.5B deal with Roche, by contrast, looks almost conservative, though Poseida's non-viral piggyBac system is further along clinically and carries less technical risk. The MaxCyte–Genentech deal, with undisclosed terms, likely represents a flow cytometry electroporation access agreement — a tools-layer deal that enables Genentech's internal cell therapy pipeline rather than acquiring specific assets.

What This Means for BD Teams Right Now

If you're a cell therapy licensor, this is the best seller's market since the 2018 CAR-T wave. Five of the top eight deals went to platform companies, not single-asset biotechs. Pharma buyers are paying premiums for manufacturing control and multi-program optionality. If your company has a differentiated cell engineering, gene delivery, or manufacturing platform, you have leverage you did not have 12 months ago. Use it. Structure deals with higher upfronts and fewer option clauses — the data supports your position.

If you're on the buy side, speed matters more than perfection. The cell therapy deal trends 2026 data shows that the best platform targets are being taken off the board in weeks, not quarters. Merck KGaA's two-deal sprint with Bio-Techne is the template: secure a licensing deal fast, then expand to full acquisition before a competitor can counter-bid. Waiting for Phase 2 data readouts to de-risk your thesis means losing the asset to a buyer willing to pay for earlier-stage conviction. Run your deal economics through Solidus to see how current upfront-to-TDV ratios compare to what you're modeling internally.

Deal structures are shifting accordingly. Milestone-heavy structures with small upfronts — the bread and butter of 2023–2024 cell therapy deals — are losing favor with licensors who now have multiple bidders. Expect to see larger upfront commitments, equity co-investments, and co-development provisions become standard in cell therapy licensing 2026 agreements. The $11.3B upfront on the Bio-Techne–Merck KGaA transaction sets a new ceiling for the category. Even if your deal is 1/20th that size, licensors will use that number as an anchor in negotiations.

Benchmark your deal against current market rates using the Ambrosia calculator — it reflects the latest cell therapy deal activity and lets you model upfront, milestones, and royalty structures against verified comparable transactions.

Frequently Asked Questions

Is this cell therapy deal surge sustainable through the rest of 2026?

The surge reflects pent-up demand releasing after a regulatory and strategic unlock, not a permanent new baseline. Expect deal velocity to moderate in Q4 2026 as the most attractive platform targets get acquired. However, the remaining pipeline of allogeneic and iPSC-derived cell therapy companies — estimated at 40+ active programs in Phase 1 or later — provides sufficient deal flow to sustain above-average activity through early 2027. The question isn't whether deals continue, but whether valuations hold at current levels once the initial FOMO subsides.

How should biotech founders position for cell therapy licensing in this market?

Founders with platform-level technology should run competitive processes now, not wait for the next clinical data readout. The Bio-Techne and Kelonia deals demonstrate that pharma buyers are willing to pay platform premiums on preclinical-stage assets when the underlying technology is differentiated. Generate at least three competing term sheets before entering exclusivity. Structure your outreach around manufacturing scalability and multi-indication applicability — these are the attributes commanding the highest TDVs in cell therapy deal trends 2026. Use Deal Benchmarks data to set your floor before negotiations begin.

Are Big Pharma cell therapy deals cannibalizing small molecule and antibody budgets?

Yes, and the data is clear. Across the five largest pharma acquirers active in cell therapy in H1 2026, external innovation spending on small molecules declined 18% year-over-year while cell and gene therapy allocations grew 45%, based on disclosed BD budgets and Evaluate Pharma pipeline tracking. This is a deliberate portfolio rotation, not an anomaly. Cell therapy is moving from the "emerging modalities" bucket into core franchise strategy for Lilly, Roche, and Merck KGaA. Expect this reallocation to accelerate as manufacturing costs decrease and reimbursement pathways stabilize.